klow topical Blend (BPC-157, TB-500, GHK-Cu, KPV) KLOW Blend Capsules — ≥99%

OxygenCeuticals - Glutathione ToneUp / Brightening Kit In stock AED 385.00 Quick Overview What it is

In MONARCH-3 trial, the HR+/HER2 postmenopausal advanced breast cancer patients who did not receive systemic therapy as the aimed population, the 18-month interim results indicated that the PFS of abemaciclib group had not been reached, and the median PFS was 14.7 months in the placebo group

Peterson, L

For further prognostic evaluation and clinical decision-making, breast cancer can be classified into three subgroups based on immunohistochemical staining results for ER, PR, and HER2: HR-positive/HER2negative (HR+/HER2, ~70%), HER2positive (HER2+, ~1520%), and triple-negative breast cancer [TNBC, HR-negative (HR-), HER2, ~15%]